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Abstract
Prior to intervention trials in individuals genetically at-risk for late-onset Alzheimer's disease, 
critical first steps are identifying where (neuroanatomic effects), when (timepoint in the lifespan) 
and how (gene expression and neuropathology) Alzheimer's risk genes impact the brain. We 
hypothesized that variants in the sortilin-like receptor (SORL1) gene would affect multiple 
Alzheimer's phenotypes before the clinical onset of symptoms. Four independent samples were 
analyzed to determine effects of SORL1 genetic risk variants across the lifespan at multiple 
phenotypic levels: 1) microstructural integrity of white matter using diffusion tensor imaging in 
two healthy control samples (n=118, age 18-86, and n=68, age 8-40); 2) gene expression using the 
Braincloud postmortem healthy control sample (n=269, age 0-92); and 3) Alzheimer's 
neuropathology (amyloid plaques and tau tangles) using a postmortem sample of healthy, mild 
cognitive impairment (MCI), and Alzheimer's individuals (n=710, age 66-108). SORL1 risk 
variants predicted lower white matter fractional anisotropy in an age-independent manner, in 
fronto-temporal white matter tracts in both samples at 5% FWE-corrected thresholds. SORL1 risk 
variants also predicted decreased SORL1 mRNA expression, most prominently during childhood 
and adolescence, and significantly predicted increases in amyloid pathology in postmortem brain. 
Importantly, the effects of SORL1 variation on both white matter microstructure and gene 
expression were observed during neurodevelopmental phases of the human lifespan. Further, the 
neuropathological mechanism of risk appears to primarily involve amyloidogenic pathways. 
Interventions targeted toward the SORL1 amyloid risk pathway may be of greatest value during 
early phases of the lifespan.
Keywords
Alzheimer's disease; neuroimaging; genetics; SORL1; amyloid; gene expression
1. Introduction
Late-onset Alzheimer's disease (AD) (i.e. onset after 65 years of age) is the most common 
form of dementia and is expected to affect over 115 million individuals worldwide by 
2050.1 Recent evidence suggests that subtle deterioration of brain structure may be present 
decades before the late-life emergence of clinical signs and symptoms in people genetically 
at-risk for this disorder.2, 3 The failure of phase 3 trials in early stages of AD has hastened 
calls for intervention prior to clinical disease onset in genetically at-risk groups in whom 
effects on brain structure or function might be present.4 These brain alterations, detectable 
using advanced neuroimaging approaches, can then serve as markers of treatment efficacy 
during clinical trials. However, prior to the initiation of such trials, systematic investigation 
of where (neuroanatomic effects), when (timepoint in the lifespan) and how (gene 
expression and neuropathology) AD risk genes impact the brain is required. After the 
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Apolipoprotein E (APOE) gene, which has not always shown consistent neural effects prior 
to disease onset,5, 6 a small number of confirmed risk genes7 for late-onset AD require such 
systematic investigation.
Among these risk genes is the sortilin-related receptor, L(DLR class), A repeats containing 
(SORL1, sorLA, LR11) gene, which codes for an ApoE receptor.8 SORL1 is thought to act 
within classical AD risk pathways by helping direct the preferential transport of amyloid 
precursor protein (APP) to endosomal recycling pathways, away from beta-secretase 
cleavage and subsequent beta-amyloid (1-42) (Aβ42) formation.9,10 Disruption of SORL1 
has also been shown to influence tau-related cellular processes.11 Furthermore, SORL1 
operates at the interface of AD and vascular disease risk through its role as a modulator of 
lipoprotein lipase trafficking.12
SORL1 genetic variants have been associated with risk for AD in several ethnic groups.13–15 
These studies have implicated single nucleotide polymorphisms (SNPs), primarily within 
two haplotype blocks at the 5′ and 3′ ends of the gene. Recently identified mutations at both 
ends of the SORL1 gene have been described in early-onset AD,16 suggesting a potentially 
causative role for this gene. SORL1 risk variants have also been associated with SORL1 
expression in postmortem brain,17, 18 and down-regulation of SORL1 in AD and mild 
cognitive impairment (MCI) brain has also been shown.19, 20 Furthermore, these variants 
have been associated with white matter atrophy and hyperintensities in late-life,21 as well as 
hippocampal volume in early adult life.22 However, white matter microstructure (i.e. 
fractional anisotropy (FA)) was recently identified as the best MRI-based predictor of 
conversion from normal cognitive state to amnestic cognitive impairment,23 underscoring 
the potential of this neuroimaging phenotype to improve detection of early risk for late-onset 
AD.
In four independently collected samples, we assessed the effects of SORL1 risk variants on 
gene expression, AD neuropathology, and white matter microstructure in vivo, using a 
lifespan approach. We hypothesized that SORL1 risk variants would influence both white 
matter microstructure and SORL1 gene expression, decades prior to the timeframe of typical 
AD-onset. Given the putative effect of decreased SORL1 expression on the APP pathway, 
we also hypothesized that SORL1 risk variants would predict increased amyloid-β plaque 
levels in postmortem brain.
2. Material and Methods
2.1. Neuroimaging (CAMH and Zucker Hillside Samples)
CAMH Sample—142 healthy volunteers were recruited at the Centre for Addiction and 
Mental Health (Toronto, Canada). All individuals (age 18-85) completed extensive clinical 
assessment protocols including the structured clinical interview for DSM-IV Axis I 
disorders (SCID-I), the Mini-Mental State examination,24 physical exam, and laboratory 
investigations to rule out the presence of any psychiatric disorder or a dementia, and a 
neuropsychological test battery (see Supplementary Methods) as previously described.25, 26 
Genotypic groups were matched for socio-demographic factors (see Table 1). The protocol 
was approved by the local Research Ethics Board, and all participants provided informed, 
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written consent. All participants were genotyped for six single nucleotide polymorphisms 
(SNPs) in the SORL1 gene (sequentially numbered SNPs 8-10 and 23-25 as defined by 
Rogaeva and colleagues, see Table 2)15 and two in APOE (rs429358 and rs7412) using 
previously published methods.27 Genotype calls were made manually, with two laboratory 
personnel independently verifying results. 10% of sample genotypes underwent quality 
control duplication. Diffusion tensor imaging (DTI) was conducted on a 1.5T GE Echospeed 
scanner (General Electric, Milwaukee, WI) using a single-shot spin echo planar sequence 
with diffusion gradients applied in 23 noncollinear directions and B=1000 s/mm2 (isotropic 
2.6 mm voxels). The entire sequence repeated 3 times to improve signal to noise ratio 
(Supplementary Methods).
Zucker Hillside Sample—To better characterize the effects of SORL1 during white 
matter development which plateaus in the 4th decade of life,28 68 healthy Caucasian subjects 
(age 8-40) were examined from an ongoing study at the Zucker Hillside Hospital, Glen 
Oaks, NY, by advertisement and word of mouth. Exclusion criteria included serious medical 
illness and any history of psychosis or major mood disorders, as determined by structured 
and semistructured assessments.29–31 Genotypic groups were matched for socio-
demographic factors (see Table 1). Further details on sample characteristics, inclusion and 
exclusion criteria have been previously published.29 Genotyping for all subjects was 
performed using the Illumina (San Diego, CA, USA) HumanOmniExpress-12v1.0 
BeadChips assay, which contained information for SNP 8 and SNP 9 (see Table 2). Missing 
genotypes were imputed using data from HapMap 3. APOE ε4 status was derived from 
rs4420638 (a proxy for APOE rs429358, where the rs4420638 G allele is linked to ε4). DTI 
was performed on a GE Signa HDx scanner using 8 channel head coils. The acquisition 
sequence included 31 noncollinear directions with B=1000 s/mm2 and 2.5mm × 1.88mm × 
1.88mm voxels (see Supplementary Methods).
2.2. Postmortem SORL1 mRNA (BrainCloud Sample)
The BrainCloud postmortem dataset consists of 269 human subjects, ranging from fetal to 
late-life, each with genomic data and transcriptomic data for the prefrontal cortex. All 
subjects had no history of significant psychological problems or psychological care, 
psychiatric admissions, or drug detoxification and no known history of psychiatric 
symptoms or substance abuse, as determined by both telephone screening and medical 
examiner documentation, as previously described.32 All individuals from the BrainCloud 
dataset were genotyped using either Illumina (San Diego, CA, USA) Infinium II 650K or 
Illumina Infinium HD Gemini 1M Duo BeadChips and mRNA quantified with the Illumina 
Human 49K Oligo array (HEEBO-7 set) according to previously published methods.33
2.3. Postmortem Amyloid Load and Tangles (Religious Orders Study {ROS} and Memory 
and Aging Project {MAP} Sample)
Participants from ROS are older nuns, priests and brothers from across the US,34 and those 
from MAP are residents of approximately 40 senior housing facilities in the Chicago 
metropolitan area, including subsidized housing facilities, retirement communities, and 
retirement homes as previously described.35 Both studies, approved by the Institutional 
Review Board of Rush University Medical Center, enroll older persons without dementia 
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who agree to annual evaluation and autopsy. All subjects were assessed with a 
comprehensive decision tree algorithm as well as a uniform, structured, clinical evaluation 
that included a self-report medical history obtained by trained nurses and research 
technicians, a neurologic examination by trained nurses and cognitive function testing by 
trained neuropsychological test technicians. Please see Bennet et al. (2006)36 for further 
detail. The follow-up rate exceeds 95% and the autopsy rate exceeds 90%. At the time of 
analysis, genomic data were available from n=710 autopsied subjects in total (249 HC, 182 
MCI, 279 AD). For regional quantification of Aβ plaques and paired helical filament tau 
(PHFtau) tangles in postmortem brains, tissue blocks were analyzed from entorhinal cortex 
proper, hippocampus (CA1/subiculum), superior frontal cortex, dorsolateral prefrontal 
cortex, inferior temporal cortex, angular gyrus cortex, anterior cingulate cortex, and 
calcarine cortex. Immunohistochemical analysis was performed to quantify Aβ and PHFtau 
for two average measures of pathology across all regions. Details of autopsy procedure and 
quantification of neuropathological measures have been previously published.37 Genomic 
data was generated using the Affymetrix (Santa Clara, CA, USA) Genechip 6.0 platform, 
with APOE and SORL1 SNP 8-10 genotypes imputed from MACH (version 1.0.16a) and 
HapMap release 22 CEU (build 36), as previously published (see Table 2).38 Genotype 
groups were matched for socio-demographic characteristics as described in Table 3.
2.5. Statistical Analysis
2.5.1. Neuroimaging (CAMH and Zucker Hillside Samples)—Each sample was 
analyzed independently using the same approach. Whole-brain voxelwise differences in FA 
between genotypic groups were assessed using tract-based spatial statistics (TBSS, see 
Supplementary Methods) with general linear models, co-varying for age, APOE ε4 status, 
and sex. Due to near-perfect linkage of the 5′ SORL1 haplotype (SNPs 8-10), all individuals 
were grouped according to rs689021 genotype using dominant (major allele [G] 
homozygotes vs. minor [A] carriers) and recessive (minor allele [A] homozygotes vs. major 
allele [G] carriers) models to determine the direction of effect. 5000 permutations were 
performed for each contrast and voxels were deemed significant if p<0.05 after threshold-
free cluster enhancement (TFCE) correction for multiple comparisons across space. In both 
samples, post hoc analysis was performed for peak voxels within select tracts using OLS 
regression (R statistical software v.2.15.1) to visualize how genotype related to FA across 
age, using voxel FA as the dependent measure, co-varying for sex and APOE ε4 status.
2.5.2. Postmortem SORL1 mRNA (BrainCloud Sample)—The only SORL1 SNP 
(within the SNP 8-10 haplotype) available in the Braincloud sample was rs689021 (SNP 9). 
Raw data were extracted and analyzed externally using R. Ordinary least squares (OLS) 
regression models were used, including restricted cubic splines to evaluate non-linear effects 
and interactions of genotype and age within ethnic subgroups (Caucasian and African 
American (AA)) together and separately, co-varying for sex, postmortem interval, and 
sample pH. Samples with an RNA integrity number (RIN)39 of less than 7.0 were excluded 
from analysis to help reduce confounding due to poor RNA quality.
2.5.3. Postmortem Amyloid Load and Tangles (Religious Orders Study {ROS} 
and Memory and Aging Project {MAP} Sample)—Of the total 710 subjects, 5 (0.7%) 
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had non-conforming SORL1 5′ haplotypes and were therefore excluded from analysis, 
resulting in a final n=705 for which SNPs 8-10 were in perfect LD. For neuropathology 
measures, the distributions of Aβ and PHFtau were heavily right skewed. We therefore 
performed median splits of each measure to create binary factors with values corresponding 
to zero-low and moderate-high pathology levels. The resulting data were analyzed using 
logistic regression to model these levels of Aβ and PHFtau as a function of SORL1 
rs689021 (SNP 9) genotype group, using an additive model with three genotypic groups, 
then using dominant (major allele [C] homozygotes vs. minor [T] carriers) and recessive 
(minor allele [T] homozygotes vs. major allele [C] carriers) models, co-varying for age, 
APOE ε4 status, sex, and education. Analysis was performed separately within each 
diagnostic group (HC, MCI, AD), and correction for multiple comparisons (2 pathological 
measures × 3 diagnostic groups=6 independent tests) was performed using FDR with 
q=0.05.
Following consistent evidence in existing literature of a strong and robust LD structure 
within the 5′ region of SORL1 (specifically the haplotype defined by SNPs 8-10),17, 40–43 as 
well as our own findings of near perfect LD within each analyzed sample (rare haplotype 
group frequencies were prohibitively low (<1%) and only present in the CAMH and 
ROS/MAP datasets), we chose to analyze one representative SNP across all four samples 
(SNP9, rs689021).
3. Results
3.1. Neuroimaging Samples (CAMH and Zucker Hillside Samples)
In both the CAMH and Zucker Hillside samples, the 5′ haplotype block (SNPs 8-10) showed 
significant associations with white matter FA (Figure 1A), with rs689021 A allele ho mo 
zygotes showing reduced FA primarily in fronto-temporal white matter tracts, including the 
bilateral superior longitudinal fasciculus, uncinate fasciculus, inferior fronto-occipital 
fasciculus, and cingulum bundle, as well as right inferior longitudinal fasciculus, and the 
genu and splenium of the corpus callosum in both samples at 5% family-wise error (FWE) 
corrected thresholds. Additionally, the Zucker Hillside sample showed effects of genotype 
within the internal capsule. No effects of SNPs 23-25 were found in the CAMH sample. 
Post hoc analysis revealed a pattern of reduced FA in rs689021 A-allele homo zygotes that 
was consistent across the age-range of both samples (i.e. no interaction with age) (Figure 
1B).
3.2. Postmortem SORL1 mRNA (BrainCloud Sample)
After removing observations with RIN<7.0, age<0, and missing sample PH information, 
ethnic subgroup sample sizes were 3(Asian), 5(Hispanic), 90(Caucasian), and 99(AA). 
Based on these group sizes, analysis was conducted in the Caucasian and AA subgroups 
only. In the combined Caucasian and AA sample (n=189), a significant non-linear genotype 
by age interaction was found (F12,176=4.06, p=0.008), co-varying for ethnicity, pH, PMI and 
sex, whereby major differences in SORL1 mRNA levels were prominent during childhood 
and adolescence into early adulthood. During this period, the A-allele homozygotes 
demonstrated reduced prefrontal SORL1 mRNA. Analyzing ethnic subgroups separately 
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revealed that the effect was driven by Caucasians (F11,78=7.03, p=0.0003) (Figure 2). No 
effect of SORL1 variation was found in the AA group (F11,87=0.1, p=0.97).
3.3. Postmortem Amyloid Load and Tangles (Religious Orders Study {ROS} and Memory 
and Aging Project {MAP} Sample)
Associations of SORL1 rs689021 (SNP 9) genotype with Aβ were found in both MCI 
(dominant model, GG genotype<A carriers, O.R.=0.34 (95% C.I.=0.16-0.73), p=0.0056 
(padj=0.03)) and AD (recessive model, AA genotype>G carriers, O.R. = 3.05 (95% 
C.I.=1.29-7.22), p=0.011 (padj=0.03)) subjects, but not in the HC group (genotypic model 
O.R.=1.2, p=0.65). For PHFtau, an association trend with rs689021 genotype was found in 
HC subjects (genotypic model, AA>GG, O.R.=2.26 (95% C.I.=0.98-5.21), p=0.055 
(padj=0.11)), but not in the MCI (genotypic model O.R.=0.96, p=0.93) or AD (genotypic 
model O.R.=1.41, p=0.42) groups. While the PHFtau result did not survive FDR correction, 
it is worth noting that the same T allele associated with greater Aβ pathology was also 
associated with increased PHFtau.
4. Discussion
We found that SORL1 risk variants influenced microstructure of white matter tracts with 
known susceptibility in AD, in two imaging-genetics datasets, with consistent effect from 
childhood onward. We then bridged the gap from genetic risk variants to brain structure by 
demonstrating that the same SORL1 risk variant predicted lower levels of mRNA 
expression, most prominently in childhood and adolescence, demonstrating a temporal 
consistency of onset of neural risk with our findings in both neuroimaging samples. Finally, 
we demonstrated that variation at the SORL1 gene predicts amyloid-β plaque levels, thus 
conferring neuropathological risk via the amyloidogenic pathway.
In both the CAMH and Zucker Hillside samples, SORL1 risk variants were associated with 
lower white matter FA in structures vulnerable in MCI and the earliest phases of AD. 
Conventional MRI studies show brain changes in AD typically occur first in medial 
temporal structures, spreading globally as the disease progresses.44–46 DTI studies in AD 
have shown that this gray matter neurodegeneration is paralleled by impairment in white 
matter tract microstructure (i.e. FA), primarily in association fibers connecting to the medial 
and lateral temporal lobes.47 These changes are also present in MCI individuals who have 
not yet developed dementia.48, 49 The results of a recent study, which identified 
parahippocampal white matter FA (part of the cingulum bundle in the medial temporal 
lobe), as the single best neuroimaging predictor of incipient cognitive impairment50 raise the 
possibility that white matter changes may precede gray matter changes in the sequence of 
preclinical AD-related neural events. Our data support that the very earliest forms of 
genetically-mediated neural risk for AD may occur through white matter pathways, from 
childhood onward. A previous examination of SORL1 and white matter found increased risk 
for postmortem white matter atrophy and white matter hyperintensities in elderly individuals 
in vivo in the elderly white MIRAGE (Multi-Institutional Research in Alzheimer's Genetic 
Epidemiology) cohort.21 Although white matter hyperintensities can be present earlier in 
adult life, they are generally uncommon in healthy young individuals,51 and as such, may 
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not be as useful as microstructural integrity of white matter when assessing subtle forms of 
early neural risk for AD.
Our lifespan analysis using BrainCloud demonstrates that the effects of SORL1 risk variants 
on SORL1 mRNA expression are most prominent from childhood through to early 
adulthood (i.e. during neurodevelopmental phases of the lifespan). Minor allele 
homozygotes showed reduced mRNA expression during this period, consistent with our 
findings of reduced microstructural integrity of white matter already present from childhood 
onward in the Zucker Hillside sample and from late adolescence onward in the CAMH 
sample. Previous studies have found allelic differences in SORL1 protein17 and mRNA 
levels52 in elderly postmortem brain; however, by using a lifespan approach, we provide the 
first evidence that the temporal impact of SORL1 risk variants on SORL1 mRNA expression 
occurs during neurodevelopmental phases of the lifespan, rather than in late-life.
Our association of SORL1 genotype with Aβ plaque levels provides direct 
neuropathological evidence that SORL1 confers risk for AD through the amyloidogenic 
pathway. Our results confirm those of in vitro studies which have found that increased levels 
of SORL1 result in decreased APP processing53 and greater production of intracellular 
Aβ42.53, 54 Loss of SORL1 expression in histologically normal late-onset AD brain-derived 
neurons20, 55 suggests that this is a primary event in late-onset AD pathology and may 
precede disease onset. SORL1's role in amyloid accumulation supports its role as a risk 
factor for AD rather than as a marker of disease progression. Our findings do not support 
SORL1 as a marker of disease progression (i.e. accumulation of tau pathology) in AD 
populations, which has recently been shown to be due to an entirely different set of genetic 
factors.56 Although it is possible that subtle changes in Aβ42 concentration resulting from 
allelic differences in SORL1 expression drive changes in microstructural integrity of white 
matter early in life, our study cannot directly answer this question. Indirect evidence for this 
possibility is provided by inverse correlations of CSF levels of SORL1 protein with Aβ42 in 
MCI subjects,57 and association of CSF levels of Aβ42 with medial frontal FA.58
There are several potential limitations to this study. First, in healthy control samples, it is 
possible that subclinical symptomatology might be present, and this caveat should be taken 
into consideration when interpreting our results. However, the similar results in both of our 
neuroimaging samples, which were from different countries and of different age range, 
provide added confidence in our results. Second, as with any group-wise analysis of means, 
the relatively small group sizes of risk allele homozygotes in some of our samples can be 
considered a limitation. However, statistically significant associations were found in each 
sample, and the direction of effect was consistent across samples. Third, due to the cross-
sectional nature of our analyses, we cannot unequivocally conclude that the imaging results 
are specific to risk for AD, as white matter impairments are prevalent in other disorders, 
such as depression, that are known to affect older adults.59 It is important to note, however, 
that SORL1 is considered an Alzheimer's risk gene, based both on genome-wide analysis 
and meta-analysis.14 Furthermore our findings align with previous investigations of regions/
tracts that are first affected in early AD and MCI, such as the cingulum bundle,50, 60 
uncinate fasciculus,61, 62 and corpus callosum.63
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Importantly, our findings must be viewed in context of the existing literature. In the initial 
Rogaeva et al. (2007)15 study (as well as the Reitz et al. (2011) meta-analysis14), the SNP 
8-10 haplotype associated with increased risk for AD diagnosis was CGC. In the Cuenco et 
al. (2008)21 imaging study, it is the A allele at SNP 9 (corresponding to the TAT haplotype) 
that is associated with increased risk for AD-associated imaging phenotypes (notably white 
matter atrophy and hyperintensities), and the T allele at SNP 8 (belonging to the same TAT 
haplotype) was associated with smaller hippocampal volumes in the only other imaging 
investigation of SORL1 gene variants by Bralten et al. (2011).22 Our neuroimaging results, 
along with our results of mRNA expression and Aβ, are in agreement with these existing 
structural imaging findings within the 5′ region of SORL1. Therefore, when all genetic 
investigations of SORL1 are taken together, it appears that allelic heterogeneity may be 
operating at these loci.
The demonstrated effects of SORL1 variation on brain structure, SORL1 mRNA, and 
amyloid pathology coupled with our lifespan approach, provide answers about when, where, 
and how this gene confers neural risk for AD. Our study identifies SORL1-related risk 
mechanisms and neuroimaging biomarkers that can be utilized in potential intervention 
studies targeted toward risk carriers, yet our findings also raise questions regarding when in 
the lifespan such interventions should be tested. At the same time, it is clear that variation at 
the SORL1 gene, except for rare cases of identified mutations, is unlikely to act as a 
causative factor alone for late-onset AD. Therefore, systematic assessment of other risk 
genes using similar multi-level lifespan approaches are first required to move closer toward 
targeted genetically-based interventions in healthy individuals at-risk for late-onset AD.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
1A. Results of TBSS white matter analysis for CAMH (A) and Zucker Hillside (B) imaging-
genetics datasets. The average white matter FA skeletons for each sample have been 
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overlaid on the MNI152 1mm T1-weighted brain standard and significant voxels are 
indicated by yellow-red colouring, corrected for multiple comparisons using TFCE at 
p<0.05. Only voxels within the mean FA skeleton (Green) were analyzed, surrounding 
voxels have been colo ured for emphasis. UNF = uncinate fasciculus; IFOF = inferior 
fronto-occipital fasciculus; CB = cingulum bundle; CC = corpus callosum; IC = internal 
capsule; ARC/SLF = arcuate fasciculus/superior longitudinal fasciculus; (R) = right; (L) = 
left.
1B. Regression model residuals of white matter fractional anisotropy at select peak voxels 
(as determined using TBSS) plotted against age, according to SORL1 rs689021 genotypic 
group ([A] allele homozygotes vs. [G] allele-carriers) in both the CAMH and Zucker 
Hillside samples. Models co-varied for sex and APOE ε4 status.
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Figure 2. 
SORL1 mRNA expression in the prefrontal cortex plotted against age, according to SNP 9 
(rs689021) genotype in the BrainCloud postmortem sample. Raw expression data are shown 
fit with loess smoothing curves for each genotype. Ordinary least squares regression model 
shows a non-linear genotype by age interaction (interaction effect: F11,78=7.03, two-tailed 
p=0.0003).
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